Apoptosis Market By Therapies (Gene Based Therapy, Drug Based Therapy, Immune Based Therapy), By Indications (Cancer, Cardiovascular, Neurodegenerative Diseases, Others), By Drug Class And Consumables (Direct Apoptogens, First Generation Indirect Apoptogens, Second Generation Indirect Apoptogens, Reagents And Kits), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global apoptosis market is expected to grow at a significant rate during 2016-2022.
Apoptosis is natural and highly regulated process of programmed cell death in body which occurs in multicellular organisms and it generates cell fragments which are known as apoptotic bodies. Process of apoptosis protects body against unusual cell division, viral infection and cells with damaged inherent material. The major factor driving the global apoptosis market is the tumors treated with radiation and cyto-toxins. Radiation is also called as photons, x-rays and gamma rays. Radiation therapy is used to treat tumors and it also kills cancer cells by using high energy radiations. Through radiation therapy large number of tumor cells dies which results in shrinkage of tumor and the dead cells are then disposed of through the immune system. These types of treatment mainly depend on the type of tumor being treated. Some of the key drivers of the global apoptosis market are development of apoptosis modulating drugs, growing prevalence of chronic conditions and growing incidences of cardiovascular and neurodegenerative disorders. Chronic conditions include cancer, HIV infection, neurodegenerative diseases, organ transplant rejection, multiple organ dysfunction syndrome, and cardiovascular diseases which drive the demand for apoptosis therapies. High investment required for research and development and the side effects associated with apoptosis therapies are the restraints of this market hampering the growth of global apoptosis market. Growing research and development activities in apoptosis such as identification of drugs includes radio sensitizers, chemo sensitizers and anti-inflammatory agents for unmet medicinal needs is the opportunity available in the global apoptosis market. Research of apoptosis bringing pathways as treatment to cancer is one of the developing therapies in upcoming years. Tumors treated with radiation and cyto-toxins show growing rate of apoptosis which is further estimated to raise the rate of apoptosis being carried out to treat cancers over the forecast period. The challenging factor for the global apoptosis market is the lack of awareness, as the defective apoptosis process may cause cancer in which infected cells continue to mutate and proliferate instead of undergoing apoptosis process, but this challenge can be overcomed by developing apoptosis modulating drugs for the treatment of chronic inflammation, cancer, autoimmunity disorders and CNS diseases.
Market Segment Insight
The global market of apoptosis is segmented on the basis of therapies, indications, drug class and consumables, and regional outlook. Based on therapies, the global apoptosis market has been segmented into three categorize such as gene based therapy, drug based therapy and immune based therapy. These therapies are used for apoptogens and treatment. Gene based therapy targets a particular family of anti apoptotic genes for example Bax, p53, Bcl2, Bad, and many more. Drug based therapies involve minute molecules which are generally analogues of antagonists, and potent cytotoxic drugs for family of anti apoptotic proteins which result in apoptosis in complete tumor growth inhibition, inhibition of tumour cells and cell proliferation. Immune based therapy (immunotherapy) is still in its developing phase. Based on the indications, the market is segmented into cancer, cardiovascular, neurodegenerative diseases and others. Based on the drug class and consumables, the market is segmented into direct apoptogens, first generation indirect apoptogens, second generation indirect apoptogens and reagents and kits. Direct apoptogens drugs have apoptosis related molecular targets which induce apoptosis. First generation indirect apoptogens drugs possess apoptosis, as a part of their efficiency and have cytotoxic nature. Second generation is the drug having non apoptotic targets.
Regional Insight
Based on geography, the industry is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America region holds the largest market share of the global apoptosis market followed by Europe, owing to presence of infrastructure mandate for research and development, rising demand of targeted cancer therapy and increasing healthcare investment in this region. Europe is anticipated to maintain its position owing to increasing potential target population and rising incidence of cancer in addition with unmet treatments. Asia Pacific is also estimated to show a significant growth rate in the upcoming years owing to the increasing government regulations related to apoptosis and growing research & development initiatives.
Competitive Insights
Some of the major players of the apoptosis market are Abbott Laboratories, Aegera therapeutics Inc, Amgen Inc, Apicept Corporation, Bioniche Life Sciences Inc., Chromo Therapeutics Limited, Infinity Pharmaceuticals Inc., Novartis Limited and many more. These companies are highly focused towards growing their production capacity through merger, acquisition and product launch in the marketplace.
CHAP 1. METHODOLOGY & SCOPE 11
1.1. RESEARCH METHODOLOGY 11
1.2. RESEARCH SCOPE & ASSUMPTIONS 11
1.3. LIST OF DATA SOURCES 11
CHAP 2. EXECUTIVE SUMMARY 12
2.1. GLOBAL APOPTOSIS MARKET SUMMARY & KEY BUYING CRITERIA 12
2.2. GLOBAL APOPTOSIS MARKET OUTLOOK 12
2.3. MARKET SEGMENTATION ANALYSIS 12
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 12
2.5. GLOBAL APOPTOSIS MARKET VALUE CHAIN ANALYSIS 12
2.6. VENDOR LANDSCAPE 12
CHAP 3. GLOBAL APOPTOSIS MARKET 13
3.1. MARKET DRIVER ANALYSIS 13
3.1.1. DEVELOPMENT OF APOPTOSIS MODULATING DRUGS 13
3.1.2. GROWING PREVALENCE OF CHRONIC CONDITIONS 13
3.1.3. TUMORS TREATED WITH RADIATION AND CYTO-TOXINS 13
3.1.4. GROWING INCIDENCES OF CARDIOVASCULAR NEURODEGENERATIVE DISORDERS 13
3.2. MARKET RESTRAINT ANALYSIS 13
3.2.1. SIDE EFFECT TO NORMAL CELLS 13
3.2.2. HIGH INVESTMENT NEEDED FOR RESEARCH AND DEVELOPMENT 13
3.3. KEY OPPORTUNITIES 13
3.3.1. GROWING RESEARCH AND DEVELOPMENT ACTIVITIES 13
3.4. CHALLENGES 13
3.4.1. LACK OF AWARENESS 13
CHAP 4. INDUSTRY ANALYSIS 14
4.1. GLOBAL APOPTOSIS MARKET– PORTER’S FIVE FORCE MODEL 14
4.2. GLOBAL APOPTOSIS MARKET– PESTEL ANALYSIS 14
4.3. GLOBAL APOPTOSIS MARKET- GAP ANALYSIS 14
CHAP 5. GLOBAL APOPTOSIS MARKET BY THERAPIES 2012-2022 ($ MILLION) 15
5.1. GLOBAL APOPTOSIS MARKET BY GENE BASED THERAPY 2012-2022 ($ MILLION) 15
5.2. GLOBAL APOPTOSIS MARKET BY DRUG BASED THERAPY 2012-2022 ($ MILLION) 15
5.3. GLOBAL APOPTOSIS MARKET BY IMMUNE BASED THERAPY 2012-2022 ($ MILLION) 15
CHAP 6. GLOBAL APOPTOSIS MARKET BY INDICATIONS 2012-2022 ($ MILLION) 16
6.1. GLOBAL APOPTOSIS MARKET BY CANCER 2012-2022 ($ MILLION) 16
6.2. GLOBAL APOPTOSIS MARKET BY CARDIOVASCULAR 2012-2022 ($ MILLION) 16
6.3. GLOBAL APOPTOSIS MARKET BY NEURODEGENERATIVE DISEASES 2012-2022 ($ MILLION) 16
6.4. GLOBAL APOPTOSIS MARKET BY OTHERS 2012-2022 ($ MILLION) 16
CHAP 7. GLOBAL APOPTOSIS MARKET BY DRUG CLASS AND CONSUMABLES 2012-2022 ($ MILLION) 17
7.1. GLOBAL APOPTOSIS MARKET BY DIRECT APOPTOGENS 2012-2022 ($ MILLION) 17
7.2. GLOBAL APOPTOSIS MARKET BY FIRST GENERATION INDIRECT APOPTOGENS 2012-2022 ($ MILLION) 17
7.3. GLOBAL APOPTOSIS MARKET BY SECOND GENERATION INDIRECT APOPTOGENS 2012-2022 ($ MILLION) 17
7.4. GLOBAL APOPTOSIS MARKET BY REAGENTS AND KITS 2012-2022 ($ MILLION) 17
CHAP 8. GLOBAL APOPTOSIS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 18
8.1. GLOBAL APOPTOSIS MARKET BY REGION 2012-2022 ($ MILLION) 18
8.2. NORTH AMERICA 18
8.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
8.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
8.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
8.2.3.1. U.S. 18
8.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
8.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
8.2.3.2. CANADA 18
8.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
8.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
8.3. EUROPE 18
8.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
8.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
8.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
8.3.3.1. GERMANY 18
8.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
8.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
8.3.3.2. UK 19
8.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
8.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
8.3.3.3. FRANCE 19
8.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
8.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
8.3.3.4. SPAIN 19
8.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
8.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
8.3.3.5. REST OF EUROPE 19
8.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 19
8.3.3.5.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 19
8.4. ASIA PACIFIC 19
8.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
8.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 19
8.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
8.4.3.1. CHINA 19
8.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.4.3.2. INDIA 20
8.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.4.3.3. JAPAN 20
8.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.4.3.4. ROAPAC 20
8.4.3.4.1. ROAPAC MARKET ESTIMATES AND FORECASTS 2012-2022($ MILLION) 20
8.4.3.4.2. ROAPAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 20
8.5. MIDDLE EAST & AFRICA 20
8.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.6. LATIN AMERICA 20
8.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.6.2.1. BRAZIL 20
8.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
CHAP 9. COMPETITIVE LANDSCAPE 22
9.1. ABBOTT LABORATORIES 23
9.1.1. COMPANY OVERVIEW 23
9.1.2. FINANCIAL PERFORMANCE 23
9.1.3. PRODUCT BENCHMARKING 23
9.1.4. STRATEGIC INITIATIVES 23
9.2. AEGERA THERAPEUTICS INC 23
9.2.1. COMPANY OVERVIEW 23
9.2.2. FINANCIAL PERFORMANCE 23
9.2.3. PRODUCT BENCHMARKING 23
9.2.4. STRATEGIC INITIATIVES 23
9.3. AMGEN INC 23
9.3.1. COMPANY OVERVIEW 23
9.3.2. FINANCIAL PERFORMANCE 23
9.3.3. PRODUCT BENCHMARKING 23
9.3.4. STRATEGIC INITIATIVES 23
9.4. APICEPT CORPORATION 23
9.4.1. COMPANY OVERVIEW 23
9.4.2. FINANCIAL PERFORMANCE 23
9.4.3. PRODUCT BENCHMARKING 23
9.4.4. STRATEGIC INITIATIVES 23
9.5. BIONICHE LIFE SCIENCES INC. 23
9.5.1. COMPANY OVERVIEW 23
9.5.2. FINANCIAL PERFORMANCE 23
9.5.3. PRODUCT BENCHMARKING 23
9.5.4. STRATEGIC INITIATIVES 23
9.6. CELGENE CORPORATION 23
9.6.1. COMPANY OVERVIEW 23
9.6.2. FINANCIAL PERFORMANCE 24
9.6.3. PRODUCT BENCHMARKING 24
9.6.4. STRATEGIC INITIATIVES 24
9.7. CHROMO THERAPEUTICS LIMITED 24
9.7.1. COMPANY OVERVIEW 24
9.7.2. FINANCIAL PERFORMANCE 24
9.7.3. PRODUCT BENCHMARKING 24
9.7.4. STRATEGIC INITIATIVES 24
9.8. ENTREMED INC 24
9.8.1. COMPANY OVERVIEW 24
9.8.2. FINANCIAL PERFORMANCE 24
9.8.3. PRODUCT BENCHMARKING 24
9.8.4. STRATEGIC INITIATIVES 24
9.9. EXELIXES INC 24
9.9.1. COMPANY OVERVIEW 24
9.9.2. FINANCIAL PERFORMANCE 24
9.9.3. PRODUCT BENCHMARKING 24
9.9.4. STRATEGIC INITIATIVES 24
9.10. GENTA INC. 24
9.10.1. COMPANY OVERVIEW 24
9.10.2. FINANCIAL PERFORMANCE 24
9.10.3. PRODUCT BENCHMARKING 24
9.10.4. STRATEGIC INITIATIVES 24
9.11. INFINITY PHARMACEUTICALS INC. 24
9.11.1. COMPANY OVERVIEW 24
9.11.2. FINANCIAL PERFORMANCE 24
9.11.3. PRODUCT BENCHMARKING 24
9.11.4. STRATEGIC INITIATIVES 24
9.12. NOVARTIS LIMITED 25
9.12.1. COMPANY OVERVIEW 25
9.12.2. FINANCIAL PERFORMANCE 25
9.12.3. PRODUCT BENCHMARKING 25
9.12.4. STRATEGIC INITIATIVES 25
9.13. PFIZER INC 25
9.13.1. COMPANY OVERVIEW 25
9.13.2. FINANCIAL PERFORMANCE 25
9.13.3. PRODUCT BENCHMARKING 25
9.13.4. STRATEGIC INITIATIVES 25
9.14. XIGEN SA 25
9.14.1. COMPANY OVERVIEW 25
9.14.2. FINANCIAL PERFORMANCE 25
9.14.3. PRODUCT BENCHMARKING 25
9.14.4. STRATEGIC INITIATIVES 25
9.15. ZENTARIS GMBH 25
9.15.1. COMPANY OVERVIEW 25
9.15.2. FINANCIAL PERFORMANCE 25
9.15.3. PRODUCT BENCHMARKING 25
9.15.4. STRATEGIC INITIATIVES 25
TABLE 1 GLOBAL APOPTOSIS MARKET BY THERAPIES 2012-2022 ($ MILLION) 26
TABLE 2 GLOBAL APOPTOSIS MARKET BY GENE BASED THERAPY BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 3 GLOBAL APOPTOSIS MARKET BY DRUG BASED THERAPY BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 4 GLOBAL APOPTOSIS MARKET BY IMMUNE BASED THERAPY BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 5 GLOBAL APOPTOSIS MARKET BY INDICATIONS 2012-2022 ($ MILLION) 26
TABLE 6 GLOBAL APOPTOSIS MARKET BY CANCER BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 7 GLOBAL APOPTOSIS MARKET BY CARDIOVASCULAR BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 8 GLOBAL APOPTOSIS MARKET BY NEURODEGENERATIVE DISEASES BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 9 GLOBAL APOPTOSIS MARKET BY OTHERS 2012-2022 ($ MILLION) 26
TABLE 10 GLOBAL APOPTOSIS MARKET BY DRUG CLASS AND CONSUMABLES 2012-2022 ($ MILLION) 26
TABLE 11 GLOBAL APOPTOSIS MARKET BY DIRECT APOPTOGENS BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 12 GLOBAL APOPTOSIS MARKET BY FIRST GENERATION INDIRECT APOPTOGENS BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 13 GLOBAL APOPTOSIS MARKET BY SECOND GENERATION INDIRECT APOPTOGENS BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 14 GLOBAL APOPTOSIS MARKET BY REAGENTS AND KITS BY GEOGRAPHY 2012-2022 ($ MILLION) 26
TABLE 15 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 16 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 17 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 18 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 19 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 27
TABLE 20 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 21 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 22 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 23 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 24 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 25 RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 27
TABLE 26 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 27
TABLE 27 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 28 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 29 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 30 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 31 ROAPAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 27
TABLE 32 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 33 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 34 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
FIGURE 1 GLOBAL APOPTOSIS MARKET BY GENE BASED THERAPY 2012-2022 ($ MILLION) 28
FIGURE 2 GLOBAL APOPTOSIS MARKET BY DRUG BASED THERAPY 2012-2022 ($ MILLION) 28
FIGURE 3 GLOBAL APOPTOSIS MARKET BY IMMUNE BASED THERAPY 2012-2022 ($ MILLION) 28
FIGURE 4 GLOBAL APOPTOSIS MARKET BY CANCER 2012-2022 ($ MILLION) 28
FIGURE 5 GLOBAL APOPTOSIS MARKET BY CARDIOVASCULAR 2012-2022 ($ MILLION) 28
FIGURE 6 GLOBAL APOPTOSIS MARKET BY NEURODEGENERATIVE DISEASES 2012-2022 ($ MILLION) 28
FIGURE 7 GLOBAL APOPTOSIS MARKET BY OTHERS 2012-2022 ($ MILLION) 28
FIGURE 8 GLOBAL APOPTOSIS MARKET BY DIRECT APOPTOGENS 2012-2022 ($ MILLION) 28
FIGURE 9 GLOBAL APOPTOSIS MARKET BY FIRST GENERATION INDIRECT APOPTOGENS 2012-2022 ($ MILLION) 28
FIGURE 10 GLOBAL APOPTOSIS MARKET BY SECOND GENERATION INDIRECT APOPTOGENS 2012-2022 ($ MILLION) 28
FIGURE 11 GLOBAL APOPTOSIS MARKET BY REAGENTS AND KITS 2012-2022 ($ MILLION) 28
FIGURE 12 MARKET SHARE BY REGIONS 28
FIGURE 13 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 14 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 15 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 16 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 17 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 18 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 19 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 20 REST OF EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 21 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 22 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 23 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 24 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 25 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 26 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 27 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022($ MILLION) 29
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)